Pulmatrix Inc, formerly Ruthigen Inc was incorporated in January 2013 and reincorporated from Nevada to Delaware in September 2013. It is a biopharmaceutical company, engaged in developing new hypochlorous acid based therapies designed to improve patient outcomes and reduce healthcare costs associated with infections related to surgical procedures. The Company's drug candidates, including RUT58-60, are broad spectrum anti-infective products that the Company has been developing for the prevention and treatment of infection in surgical and trauma procedures. The Company is engaged in development of its drug candidates for use initially to prevent infections in abdominal surgery due to the large addressable market, post-surgical infection associated with abdominal surgery, the high-impact opportunity that abdominal surgery offers it in the clinical trial setting to expose multiple internal organs to RUT58-60 at one time, and feedback from surgeons identifying post-surgical infection in abdominal surgery. Its competitor include Novabay, Oculus, Puricore, Achaogen, Basilea, Cempra, Cubist Pharmaceuticals, Durata Therapeutics, Forest Laboratories & Astra Zeneca, GlaxoSmithKline, Merck, Paratek, Rempex, Rib-X, Tetraphase Pharmaceuticals, and Trius. The Company in addition to regulations in the United States is subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its products.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.